Literature DB >> 27456244

Angiotensin (1-7) and Alamandine: Similarities and differences.

Tawar Qaradakhi1, Vasso Apostolopoulos2, Anthony Zulli2.   

Abstract

A primary peptide of the renin angiotensin system (RAS), Angiotensin (Ang) II, is a vasoconstrictor and promotor of atherosclerosis. To counter this, the RAS also consists of peptides and receptors which increase nitric oxide release from the endothelium and decrease nicotinamide adenine dinucleotide phosphate oxidase-related superoxide production. Two peptides, Ang (1-7) and alamandine are vasodilators, by activating the nitric oxide pathway via different receptors in the endothelium. Thus, herein we focus on the similarities and differences between alamandine and Ang (1-7) and the counterbalancing hypothesis on Ang II during endothelial dysfunction and atherosclerosis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alamandine; Alamandine (44192273); Angiotensin (1-7); Angiotensin 1-7 (123805); Angiotensin I (3081372); Angiotensin II (172198); Endothelial dysfunction; Renin angiotensin system

Mesh:

Substances:

Year:  2016        PMID: 27456244     DOI: 10.1016/j.phrs.2016.07.025

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  19 in total

Review 1.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

2.  The renin-angiotensin system and prolylcarboxypeptidase.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2017-05       Impact factor: 4.599

Review 3.  Mitochondrial angiotensin receptors and cardioprotective pathways.

Authors:  Nelson Escobales; Rebeca E Nuñez; Sabzali Javadov
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-04-12       Impact factor: 4.733

4.  The antiobese effect of AT1 receptor blockade is augmented in mice lacking Mas.

Authors:  Carla Dapper; Franziska Schuster; Ines Stölting; Florian Vogt; Lucas Araújo Castro E Souza; Natalia Alenina; Michael Bader; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-03-13       Impact factor: 3.000

Review 5.  The Importance of Integrated Regulation Mechanism of Coronary Microvascular Function for Maintaining the Stability of Coronary Microcirculation: An Easily Overlooked Perspective.

Authors:  Houyong Zhu; Hanxin Wang; Xinyu Zhu; Qilan Chen; Xiaojiang Fang; Xiaoqun Xu; Yan Ping; Beibei Gao; Guoxin Tong; Yu Ding; Tielong Chen; Jinyu Huang
Journal:  Adv Ther       Date:  2022-10-24       Impact factor: 4.070

Review 6.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

Review 7.  Roles of eNOS in atherosclerosis treatment.

Authors:  Fen-Fang Hong; Xiao-Yu Liang; Wei Liu; Sha Lv; Shu-Jin He; Hai-Bin Kuang; Shu-Long Yang
Journal:  Inflamm Res       Date:  2019-04-01       Impact factor: 4.575

8.  Alamandine reduces leptin expression through the c-Src/p38 MAP kinase pathway in adipose tissue.

Authors:  Tsuyoshi Uchiyama; Fumikazu Okajima; Chihiro Mogi; Ayaka Tobo; Shoichi Tomono; Koichi Sato
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

Review 9.  Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.

Authors:  Matthias Pinter; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2017-10-04       Impact factor: 17.956

10.  Protective effect of alamandine on doxorubicin‑induced nephrotoxicity in rats.

Authors:  Ava Soltani Hekmat; Ameneh Chenari; Hiva Alipanah; Kazem Javanmardi
Journal:  BMC Pharmacol Toxicol       Date:  2021-05-29       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.